Jordann Merkert

Can EEG and machine learning (ML) predict outcome with psychotherapy? In this new paper in @NatMentHealth, we developed and validated EEG ML biomarkers for predicting outcome with two types of psychotherapy for PTSD. A 🧵 below, and link to the paper: rdcu.be/dacmw

We are honored to be featured in @biospace's NextGen “Class of 2023” list recognizing this year’s 25 most exciting new companies in #biotech and #pharma across therapeutic areas. In 2023, we can't wait to build on this strong momentum! Read more: biospace.com/article/top-li…

Attending @jpmorgan's 41st Annual Healthcare Conference? Join us on Wednesday, January 11th at 5 p.m. PT for CEO @AmitEtkin's presentation highlighting new data and a general corporate update. Read more: altoneuroscience.com/press-releases… #JPM2023

#ICYMI, founder & CEO @AmitEtkin presented in a Meet the Expert session at #ACNP2022. To learn more and connect with our team, be sure to attend our @ACNPorg presentation of new data Wednesday evening at 5:30 MT during Poster Session III, W105.

Attending #ACNP2022? Kick off Tuesday morning by attending the “Meet the Expert” session on #PrecisionPsychiatry from 8:30-9:45 a.m. MT, and meet our CEO @AmitEtkin to discuss all things #biomarkers in #neuropsychiatry! Learn more and register here: acnp.org/annual-meeting/

Part 4 of 5 of The Alto Advantage series focuses on ‘Invested in Impact,’ a value that ties our work together. CFO Nick Smith shares how the Alto team is committed to bringing forward this impact and #innovation for patients. Read more here: altoneuroscience.com/post/the-alto-…

We are excited to announce a $35M Series B #financing co-led by Lightswitch Capital and @AlkeonCapital, including participation from @Novartis. We will use these funds to propel our pipeline + platform in #PrecisionPsychiatry forward. Read more: altoneuroscience.com/press-releases…

In today's @PharmaVoice feature, CEO @AmitEtkin shares how risking it all to disrupt the status quo is paying off. Read more on our leading #PrecisionPsychiatry drug development approach based on Alto's proprietary platform + novel brain biomarkers here: pharmavoice.com/news/alto-nove…

@AmitEtkin @royperlis @KarunaPharma @Bionomics1 @NeumoraTx Great conversation!!

Thank you, @royperlis, for moderating a great panel on CNS #DrugDevelopment at MGH's Future of #MentalHealth program, with leaders from @KarunaPharma, @Bionomics1, and @NeumoraTx. Learn more and register: lms.mghcme.org/content/future…

Our recently published #AltoInMind blog post is part 1 of a 5-part series called The Alto Advantage, where we cover Alto’s guiding principles for pioneering #PrecisionPsychiatry. Read CEO @AmitEtkin’s take on how we #RethinkEverything here: bit.ly/3R4IJ7f

@PeteDeSpain Literally!! 🏔

@jphillipsbio Thank you, Jordann! Still coming back down to Earth 😊

The Paiutes call it Too-man-i-goo-yah, or “the very old man.” Well the old man nearly kicked my butt #MtWhitney #BucketList

This recent piece by @NedPagliarulo in @BioPharmaDive about the importance of and still very rare role of founder-led biotechs sparked some thoughts from my own experience doing exactly that. Interesting parallels with @DrSynbio's story. A 🧵 below: biopharmadive.com/news/becraft-s…

Discussion around the recent paper summarizing research on serotonin levels (indexed in different ways) in depression is quite interesting...both for what is mentioned and what is not. The paper: nature.com/articles/s4138… My thoughts in a 🧵

Our CEO Dr.@AmitEtkin will participate on a panel at #BIO2022 (@IAmBiotech) tomorrow at 1:45 p.m. PT. He will be joined by other #CNS executives and moderator @ADeAngelis_bio (@statnews) to discuss #DrugDevelopment in the space. Learn more: bio.org/events/bio-int…

@AltoNeuro @AmitEtkin Such an honor to be on this team!

Meet Jordann Phillips, our go-to for all things comms + patient advocacy. On the heels of #MentalHealthAwarenessMonth, she shares, “As someone who's struggled with depression and tried meds to no avail, I can attest to the unmet need. Alto is changing the game.” #MeetTheTeam

@AmitEtkin @AltoNeuro The best team!!🙌

Come join us @AltoNeuro!!

Stunning how high/fast adolescent depression has been increasing. And with little study of treatment options (compared to adults). @nytimes www-nytimes-com.cdn.ampproject.org/c/s/www.nytime…

This #WorldHealthDay, we’re focused on creating a #HealthierTomorrow by working to bring every person the right treatment for them, right away. Urgent action is needed to address the growing mental health crisis and mental healthcare is a key component of global well-being.

Prescribing drugs for mental illness is a guessing game. A new precision medicine approach from @AltoNeuro seeks to go beyond clinical assessments & one-size-fits-all pharmacopeias to diagnoses based on advanced imaging & molecular biomarkers. buff.ly/3tHIsOh